MD, New York University School of Medicine
NYU Medical Center
English, Russian, Spanish
American Board of Internal Medicine
Dieterich DT. Treatment of Hepatitis C and Anemia in Human Immunodeficiency Virus-Infected Patients. J Infect Dis 2002; 185(suppl 2): S128-S137.
Soriano V, Sulkowski M, Bergin C, Hatzakis A, Cacoub P, Katlama C, Cargnel A, Mauss S, Dieterich D, Moreno S, Ferrari C, Poynard T, Rockstroh J. Care of Patients with Chronic hepatitis C and HIV co-infection: recommendations from the HIV-HCV International Panel. AIDS 2002; 16: 813-828.
Palmon R, Koo BC, Shoultz DA, Dieterich DT D. Lack of Hepatotoxicity Associated with Nonnucleoside Reverse Transcriptase Inhibitors. J Acquir Immune Defic Syndr 2002; 29: 340-345.
Dieterich DT. Human Immunodeficiency Virus and the Liver: Lessons Learned and Still be Learned. Seminars in Liver Disease 2003; 23(2): 107-114.
Dieterich DT. HIV and Hepatitis B Virus: Options for Managing Coinfection. Topics in HIV Medicine 2003; 11(1): 16-19.
Nickolas K, Dieterich DT. Toxicity of Non-Nucleoside Analogue Reverse Transcriptase Inhibitors . Seminars in Liver Disease 2003; 23(2): 173-182.
Dieterich DT. Managing Antiretroviral-Associated Liver Disease . Journal of Acquired Immune Deficiency Syndromes; 22.
An Open-Label Multicenter Study to Evaluate Long-term Outcomes with ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (TOPAZ II)
A Multicenter, Randomized, Double-blind, Placebo-controlled, Multi-dose Study to Determine the Depth of Hepatitis B Surface Antigen (HBsAg) Reduction Following Intravenous ARC-520 in Combination with Entecavir or Tenofovir in Patients with HBeAg Positive, Chronic Hepatitis B Virus (HBV) Infection
Phase I, Randomized, Open-Label, Active-Controlled, Dose Escalation Study to Evaluate the Safety, Tolerability, and Immunogenicity of INO-1800 Alone or in Combination With INO-9112 Delivered IM Followed by Electroporation in Select Nucleos(t)ide Analogue-treated, Chronic Hepatitis B Patients
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Dieterich during 2015 and/or 2016. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Industry-Sponsored Lectures: MSSM faculty occasionally give lectures at events sponsored by industry, but only if the events are free of any marketing purpose
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.